Clinical Trial Update: Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients [Phase 3]

View source ↗

Summary

Phase III trial evaluating PXT3003 for Charcot-Marie-Tooth Disease is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Charcot-marie-tooth Disease

Drugs mentioned

• PXT3003

Snippet

Sponsor: Pharnext S.C.A. | Conditions: Charcot-Marie-Tooth Disease | Phase 3 | Status: ACTIVE_NOT_RECRUITING